Wall Street analysts expect Moderna (MRNA) to post quarterly loss of $2.92 per share in its upcoming report, which indicates a year-over-year increase of 4.9%. Revenues are expected to be $126.98 ...

Kennedy won Senate confirmation to his job, in part, by promising not to change the nation’s vaccine schedule. Since taking ...

Moderna MRNA is expected to report first-quarter 2025 earnings on May 1, before the opening bell. The company’s earnings beat ...

In the latest trading session, Moderna (MRNA) closed at $27.19, marking a -0.75% move from the previous day. This change lagged the S&P 500's 0.74% gain on the day. On the other hand, the Dow ...

Advancements in mRNA vaccine technology are reshaping medicine, addressing challenges and expanding applications from ...

Moderna faces challenges with respiratory vaccine sales and strong competition. Click here to read an analysis of MRNA stock ...

Details for the poster presentation are as follows: Presentation Title: An mRNA-encoded masked IL-12 improves systemic tolerability while maintaining anti-tumor efficacy in preclinical studies Poster ...

Looking at options history for Moderna MRNA we detected 13 trades. If we consider the specifics of each trade, it is accurate to state that 53% of the investors opened trades with bullish ...

Furthering its goal to grow the reach of its mRNA vaccines and guard against future pandemics, Moderna cleared a key ...